Found 7 results
Author Title [ Type(Desc)] Year
Filters: Author is Campbell, James D  [Clear All Filters]
Journal Article
R. W. Frenck, Belshe, R., Brady, R. C., Winokur, P. L., Campbell, J. D., Treanor, J., Hay, C. M., Dekker, C. L., Walter, E. B., Cate, T. R., Edwards, K. M., Hill, H., Wolff, M., Leduc, T., and Tornieporth, N., Comparison of the immunogenicity and safety of a split-virion, inactivated, trivalent influenza vaccine (Fluzone®) administered by intradermal and intramuscular route in healthy adults., Vaccine, vol. 29, no. 34, pp. 5666-74, 2011.
L. A. Jackson, Campbell, J. D., Frey, S. E., Edwards, K. M., Keitel, W. A., Kotloff, K. L., Berry, A. A., Graham, I., Atmar, R. L., C Creech, B., Thomsen, I. P., Patel, S. M., Gutierrez, A. F., Anderson, E. L., Sahly, H. M. El, Hill, H., Noah, D. L., and Bellamy, A. R., Effect of Varying Doses of a Monovalent H7N9 Influenza Vaccine With and Without AS03 and MF59 Adjuvants on Immune Response: A Randomized Clinical Trial., JAMA, vol. 314, no. 3, pp. 237-46, 2015.
K. M. Zangwill, Treanor, J. J., Campbell, J. D., Noah, D. L., and Ryea, J., Evaluation of the safety and immunogenicity of a booster (third) dose of inactivated subvirion H5N1 influenza vaccine in humans., J Infect Dis, vol. 197, no. 4, pp. 580-3, 2008.
L. A. Jackson, Frey, S. E., Sahly, H. M. El, Mulligan, M. J., Winokur, P. L., Kotloff, K. L., Campbell, J. D., Atmar, R. L., Graham, I., Anderson, E. J., Anderson, E. L., Patel, S. M., Fields, C., Keitel, W., Rouphael, N., Hill, H., and Goll, J. B., Safety and immunogenicity of a modified vaccinia Ankara vaccine using three immunization schedules and two modes of delivery: A randomized clinical non-inferiority trial., Vaccine, vol. 35, no. 13, pp. 1675-1682, 2017.
W. A. Keitel, Campbell, J. D., Treanor, J. J., Walter, E. B., Patel, S. M., He, F., Noah, D. L., and Hill, H., Safety and immunogenicity of an inactivated influenza A/H5N1 vaccine given with or without aluminum hydroxide to healthy adults: results of a phase I-II randomized clinical trial., J Infect Dis, vol. 198, no. 9, pp. 1309-16, 2008.
J. J. Treanor, Campbell, J. D., Zangwill, K. M., Rowe, T., and Wolff, M., Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine., N Engl J Med, vol. 354, no. 13, pp. 1343-51, 2006.
M. D. Tapia, Sow, S. O., Lyke, K. E., Haidara, F. Cheick, Diallo, F., Doumbia, M., Traore, A., Coulibaly, F., Kodio, M., Onwuchekwa, U., Sztein, M. B., Wahid, R., Campbell, J. D., Kieny, M. - P., Moorthy, V., Imoukhuede, E. B., Rampling, T., Roman, F., De Ryck, I., Bellamy, A. R., Dally, L., Mbaya, O. Tshiani, Ploquin, A., Zhou, Y., Stanley, D. A., Bailer, R., Koup, R. A., Roederer, M., Ledgerwood, J., Hill, A. V. S., W Ballou, R., Sullivan, N., Graham, B., and Levine, M. M., Use of ChAd3-EBO-Z Ebola virus vaccine in Malian and US adults, and boosting of Malian adults with MVA-BN-Filo: a phase 1, single-blind, randomised trial, a phase 1b, open-label and double-blind, dose-escalation trial, and a nested, randomised, double-bli, Lancet Infect Dis, vol. 16, no. 1, pp. 31-42, 2016.